WallStreetZenWallStreetZen

NASDAQ: AUPH
Aurinia Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Aurinia Pharmaceuticals revenue was $235.13M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $59.9M, down 11.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AUPH annual revenue was $235.1M, with 34% growth year-over-year.

AUPH past revenue growth

How has AUPH's revenue growth performed historically?

Company
33.97%
Industry
437.31%
Market
20.27%
AUPH's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AUPH's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AUPH's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AUPH revenue history

Current Revenue
$235.1M
Current Earnings
$5.8M
Current Profit Margin
2.4%

Be the first to know when AUPH announces revenue.

AUPH Revenue History By Year

AUPH Yearly RevenueAUPH RevenueAUPH ChangeAUPH Revenue Growth
2024-12-31$235.13M$59.62M+33.97%
2023-12-31$175.51M$41.48M+30.95%
2022-12-31$134.03M$88.43M+193.89%
2021-12-31$45.61M-$4.51M-9.00%
2020-12-31$50.12M$49.80M+15,660.38%
2019-12-31$318.00k-$145.00k-31.32%
2018-12-31$463.00k$45.00k+10.77%
2017-12-31$418.00k$245.00k+141.62%
2016-12-31$173.00k-$62.00k-26.38%
2015-12-31$235.00k-$43.00k-15.47%
2014-12-31$278.00k-$691.00k-71.31%
2013-12-31$969.00k-$5.16M-84.18%
2012-12-31$6.13MN/AN/A

1 of 1

Aurinia Pharmaceuticals Revenue FAQ

What was AUPH's revenue last quarter?

On Invalid Date, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 2024 revenue of $59.87 million up 32.76% year over year. In the same quarter last year, Aurinia Pharmaceuticals's revenue was $45.10 million.

What was Aurinia Pharmaceuticals's revenue in 2024?

Aurinia Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $235.13 million, a 33.97% increase year over year.

How much does Aurinia Pharmaceuticals make in a day?

Based on Aurinia Pharmaceuticals annual revenue for the past five years, AUPH makes an average of $350,903.56 per day.

What was Aurinia Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Aurinia Pharmaceuticals's revenue has grown 33.97% year over year. This is 403.34 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Aurinia Pharmaceuticals's revenue in the past year totaled $235.13 million.

How much does Aurinia Pharmaceuticals make in a year?

Aurinia Pharmaceuticals's revenue by year for the past five years is:
  • Aurinia Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $235.13 million, a 33.97% increase year over year.
  • Aurinia Pharmaceuticals's annual revenue for Dec 31, 2023 was $175.51 million, a 30.95% increase from 2022.
  • Aurinia Pharmaceuticals's annual revenue for 2022 was $134.03 million, a 193.89% increase from 2021.
  • Aurinia Pharmaceuticals's annual revenue for 2021 was $45.61 million, a 9% decrease from 2020.
  • Aurinia Pharmaceuticals's annual revenue for 2020 was $50.12 million, a 15,660.38% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.